| Autor: |
Dragunsky EM; Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA. eugenia.dragunsky@fda.hhs.gov, Ivanov AP, Abe S, Potapova SG, Enterline JC, Hashizume S, Chumakov KM |
| Jazyk: |
angličtina |
| Zdroj: |
The Journal of infectious diseases [J Infect Dis] 2006 Sep 15; Vol. 194 (6), pp. 804-7. Date of Electronic Publication: 2006 Aug 16. |
| DOI: |
10.1086/506949 |
| Abstrakt: |
Recently, we developed and optimized a new method for the evaluation of the protective properties of serotype 2 inactivated poliovirus vaccines (IPV). The method is based on the immunization and subsequent challenge of transgenic (Tg) mice susceptible to poliovirus. We describe a similar method for the assessment of the protectiveness of serotype 1 IPV and demonstrate that experimental IPV produced from attenuated Sabin strain (sIPV) of serotype 1 poliovirus induced serum neutralizing antibodies, immunoglobulin (Ig) G, IgM, and salivary IgA at titers comparable to those induced by conventional IPV (cIPV) produced from the wild-type Mahoney strain. In contrast to our previous results with serotype 2 sIPV, serotype 1 sIPV provided even better protection of Tg mice than cIPV against challenge with wild-type Mahoney strain. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
